Paul Nurse comments on Pfizer's bid for AstraZeneca

13 May 2014

President of the Royal Society, Sir Paul Nurse, has written to the chairs of the Commons Business Select Committee and Science Select Committee about Pfizer's bid for AstraZeneca ahead of the CEOs of both organisations appearing at evidence sessions.

Nurse Sir Paul Nurse, President of the Royal Society.

Ian C. Read, Chairman of the Board and Chief Executive Officer, Pfizer, and Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca, will appear this week in one-off evidence sessions before the Commons Science and Technology Committee and the Business, Innovation and Skills Committee.

The Science and Technology Committee will consider the potential impact on the UK science base of a merger between the two pharmaceutical companies.

The Business, Innovation and Skills Committee will hear from trade unions, Ian C. Read, Pascal Soriot and the Secretary of State for Business, Innovation and Skills, Vince Cable.

Ahead of the evidence sessions, Sir Paul Nurse has written to Adrian Bailey, Chair of the Business, Innovation and Skills Committee (PDF) and Andrew Miller, Chair of the Science and Technology Committee (PDF) to share his thoughts on this complex issue.

Share this page

Latest news

  • Making the UK the best place to do research and innovation 10 February 2015 The new Government elected in May 2015 has an opportunity to build on our strengths and help make the UK the best place in the world to do research and innovation according to a statement published by the National Academies.
  • Do drones bother birds? 04 February 2015 A paper in Biology Letters is the first to start work on a set of ethical guidelines of how drones can be used to monitor wild animals.

For a full archive please see the news pages.